Inventor · disambiguated record
Marco Demaria
Also filed as: DEMARIA MARCO
20 granted patents·6 pending applications·150 citations·filing 2012–2023
95Inventor score
Files withBUCK INST RES AGING17UNITY BIOTECHNOLOGY INC5MAYO FOUND MEDICAL EDUCATION & RES2BUCK INST FOR RES ON AGING1UNIV GRONINGEN1
Top patents by PatentIndex Score
26 records- 0198US10010546B2Treatment of ophthalmic conditions by selectively removing senescent cells from the eyeBUCK INST RES AGING·Filed 2017·Granted Jul 3, 2018·23 cites·11 claims
- 0297US9849128B2Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cellsBUCK INST RES AGING·Filed 2017·Granted Dec 26, 2017·24 cites·15 claims
- 0396US9993472B2Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2BUCK INST RES AGING·Filed 2015·Granted Jun 12, 2018·20 cites·7 claims
- 0496US9980962B2Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary diseaseBUCK INST RES AGING·Filed 2017·Granted May 29, 2018·6 cites·8 claims
- 0596US9855266B2Treatment for osteoarthritis by intra-articular administration of a cis-imidazolineBUCK INST RES AGING·Filed 2017·Granted Jan 2, 2018·12 cites·14 claims
- 0695US10328073B2Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Jun 25, 2019·9 cites·16 claims
- 0795US10130628B2Treatment of joint painUNITY BIOTECHNOLOGY INC·Filed 2017·Granted Nov 20, 2018·6 cites·8 claims
- 0894US10478432B2Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eyeBUCK INST RES AGING·Filed 2018·Granted Nov 19, 2019·7 cites·18 claims
- 0994US9901080B2Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cellsBUCK INST RES AGING·Filed 2016·Granted Feb 27, 2018·16 cites·20 claims
- 1092US10258618B2Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimenBUCK INST RES AGING·Filed 2018·Granted Apr 16, 2019·5 cites·17 claims
- 1191US10328058B2Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaquesMAYO FOUND MEDICAL EDUCATION & RES·Filed 2017·Granted Jun 25, 2019·5 cites·12 claims
- 1291US10213426B2Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell populationBUCK INST RES AGING·Filed 2017·Granted Feb 26, 2019·5 cites·13 claims
- 1390US11351167B2Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissueBUCK INST RES AGING·Filed 2019·Granted Jun 7, 2022·1 cites·14 claims
- 1490US10478433B2Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision lossUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Nov 19, 2019·4 cites·20 claims
- 1586US9884065B2Inhibiting activity of senescent cells using a glucocorticoidBUCK INST RES AGING·Filed 2016·Granted Feb 6, 2018·5 cites·15 claims
- 1682US12285427B2Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitorBUCK INST RES AGING·Filed 2023·Granted Apr 29, 2025·0 cites·4 claims
- 1782US9901081B2Transgenic mouse for determining the role of senescent cells in cancerBUCK INST RES AGING·Filed 2016·Granted Feb 27, 2018·2 cites·12 claims
- 1879US11980616B2Treating liver disease by selectively eliminating senescent cellsBUCK INST RES AGING·Filed 2020·Granted May 14, 2024·0 cites·23 claims
- 1979US2019343832A1Therapy for removing senescent cells and treating senescence-associated disease using an mdm2 inhibitorUNITY BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
- 2078US11963957B2Treating cardiovascular disease by selectively eliminating senescent cellsBUCK INST RES AGING·Filed 2020·Granted Apr 23, 2024·0 cites·24 claims
- 2177US2021030752A1Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissueBUCK INST RES AGING·Filed 2020·Application pending·0 cites
- 2263US10655144B2Nucleic acid construct with a p16 promoter that causes a prodrug converting enzyme to be expressed specifically in senescent cellsBUCK INST RES AGING·Filed 2018·Granted May 19, 2020·0 cites·10 claims
- 2351US2018193458A1Compositions and methods for treating senescence-associated diseases and disordersUNITY BIOTECHNOLOGY INC·Filed 2016·Application pending·0 cites
- 2449US2019000846A1Pharmaceutical Products and Drug Combinations for Treating Atherosclerosis by Stabilizing Atherosclerotic Plaques and Promoting Plaque RegressionMAYO FOUND MEDICAL EDUCATION & RES·Filed 2018·Application pending·0 cites
- 2548US2014335074A1Methods for improving medical therapiesBUCK INST FOR RES ON AGING·Filed 2012·Application pending·0 cites
- 2645US2020041492A1Biomarkers for cellular senescenceUNIV GRONINGEN·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Marco Demaria files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →